Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antisense and RNAi Therapeutics Market

Antisense and RNAi Therapeutics Market Size

Report ID: GMI9517
Published Date: May 2024
Report Format: PDF

Download Free Sample

Antisense and RNAi Therapeutics Market Size

Antisense And RNAi Therapeutics Market size was valued at USD 4.4 billion in 2023 and is anticipated to showcase growth at 18.2% CAGR from 2024 and 2032. Increasing prevalence of neurodegenerative and genetic disorders, growing investments in research related to gene expression and delivery technologies, growth in regulatory approvals for RNAi and antisense therapeutics is driving the market.

To get key market trends

Download Free Sample

Additionally, rising awareness towards RNA-based therapeutics is also adding to the revenue growth in the market. Initiatives from patient advocacy groups and campaigns to raise disease awareness are advocating access to innovative treatments and expediting their integration into clinical practice thereby contributing to rise in awareness for advanced RNA-based therapies.

Antisense therapy utilizes short synthetic nucleic acid sequences known as antisense oligonucleotides to selectively target and regulate the expression of genes responsible for diseases. RNA interference is an intrinsic cellular mechanism that controls gene expression. In this process, small RNA molecules like small interfering RNAs (siRNAs) or microRNAs (miRNAs) hinder the translation or trigger the degradation of particular mRNA molecules.

Antisense and RNAi Therapeutics Market Report Attributes
Report Attribute	Details
Base Year:	2023
Antisense and RNAi Therapeutics Market Size in 2023:	USD 4.4 Billion
Forecast Period:	2024 – 2032
Forecast Period 2024 – 2032 CAGR:	18.2%
2024 – 2032 Value Projection:	USD 19.7 Billion
Historical Data for:	2021 – 2023
No. of Pages:	117
Tables, Charts & Figures:	214
Segments covered:	Technology, Route of administration, Application, and Region
Growth Drivers:	Increasing prevalence of neurodegenerative and genetic disorders Growing investments in research related to gene expression and delivery technologies Growth in regulatory approvals for RNAi and antisense therapeutics Rising awareness towards RNA-based therapeutics
Pitfalls & Challenges:	Requirement for significant investments in clinical studies High cost of RNA-based therapies

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The antisense and RNAi therapeutics market size was valued at USD 4.4 billion in 2023 and will register 18.2% CAGR from 2024

The RNA interference technology segment in the market held 62.4% share in 2023 and will expand rapidly through 2032, owing to its broader application spectrum compared to antisense RNA, making it more versatile and applicable.

North America antisense and RNAi therapeutics market accounted for 42.1% share in 2023 and is predicted to reach USD 8.2 billion by 2032, driven by the presence of large number of pharmaceutical manufacturers in the country offering advanced treatment options.

Alnylam Pharmaceuticals, Inc, Arbutus Biopharma, Arrowhead Pharmaceuticals, Inc, Benitec Biopharma Inc, BioNTech SE, CRISPR Therapeutics, GlaxoSmithKline plc, Ionis Pharmaceuticals, Inc, Novartis AG, OliX Pharmaceuticals, Inc, Orna Therapeutics, Inc, and Percheron Therapeutics Ltd.